-transparent.png){kind=logo}
Severe autoimmune myasthenia gravis is difficult to manage and may require immunosuppression with cyclosporine. However, cyclosporine dependency is associated with the risk of nephrotoxicity. Mycophenolate mofetil is a non-nephrotoxic alternative which should be considered to rescue cyclosporine-dependent, severe myasthenia gravis sufferers with renal impairment from progression to end-stage renal failure. However, the evidence is limited and studies have not assessed the outcome of a direct substitution in these cyclosporine-dependent patients. We study three such patients who successfully converted to mycophenolate mofetil, and briefly examine the evidence behind this option. We believe that total cyclosporine withdrawal is feasible, but strongly recommend overlapping mycophenolate mofetil treatment with cyclosporine.
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
January 2005,
Lupus,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
September 1998,
Transplantation proceedings,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
February 2006,
The Annals of pharmacotherapy,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
September 2008,
Acta neurologica Taiwanica,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
January 2009,
Current neurology and neuroscience reports,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
December 2008,
Neuropsychiatric disease and treatment,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
October 2008,
Expert opinion on pharmacotherapy,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
January 2005,
Clinical neuropharmacology,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
January 2001,
Neurology,
A K H Lim, and
G Donnan, and
B Chambers, and
F L Ierino
August 2012,
Journal of neuroimmunology,
